

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Packet – August 10, 2022

Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: No live August meeting. August 2022 is a packet-only meeting.

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. DUR Board Meeting Minutes – See Appendix A

- A. July 13, 2022 DUR Board Meeting Minutes
- B. July 13, 2022 DUR Board Recommendations Memorandum

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

2. Update on Medication Coverage Authorization Unit/Use of Statins in Members with Diabetes Mellitus (DM) – See Appendix B

- A. Pharmacy Helpdesk Activity for July 2022
- B. Medication Coverage Activity for July 2022
- C. Use of Statins in Members with DM

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

3. 30-Day Notice to Prior Authorize Camzyos™ (Mavacamten) – See Appendix C

- A. Introduction
- B. Camzyos™ (Mavacamten) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

4. Annual Review of Intravenous (IV) Iron Products – See Appendix D

- A. Current Prior Authorization Criteria
- B. Utilization of IV Iron Products
- C. Prior Authorization of IV Iron Products
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of IV Iron Products

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

5. Annual Review of Ophthalmic Anti-Inflammatory Products – See Appendix E

- A. Current Prior Authorization Criteria

- B. Utilization of Ophthalmic Anti-Inflammatory Products
- C. Prior Authorization of Ophthalmic Anti-Inflammatory Products
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Ophthalmic Anti-Inflammatory Products

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

6. Annual Review of Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications – See Appendix F

- A. Current Prior Authorization Criteria: Opioid Analgesics
- B. Current Prior Authorization Criteria: MAT Medications
- C. Utilization of Opioid Analgesics and MAT Medications
- D. Prior Authorization of Opioid Analgesics and MAT Medications
- E. Market News and Updates
- F. College of Pharmacy Recommendations
- G. Utilization Details of Opioid Analgesics and MAT Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

7. Annual Review of Topical Corticosteroids – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of Topical Corticosteroids
- C. Prior Authorization of Topical Corticosteroids
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Topical Corticosteroids

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

8. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix H

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

9. Future Business* (Upcoming Product and Class Reviews)

- A. Amyloidosis Medications
- B. Breast Cancer Medications
- C. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- D. Synagis® (Palivizumab)

*Future product and class reviews subject to change.

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.